Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Free Report) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 1,100,000 shares, a drop of 17.3% from the September 30th total of 1,330,000 shares. Currently, 4.0% of the company’s stock are short sold. Based on an average daily volume of 662,700 shares, the days-to-cover ratio is presently 1.7 days.
Viracta Therapeutics Stock Performance
VIRX stock traded down $0.02 during trading on Monday, reaching $0.24. The company had a trading volume of 22,041,756 shares, compared to its average volume of 401,796. The company has a market cap of $9.57 million, a price-to-earnings ratio of -0.21 and a beta of 0.70. Viracta Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.31. The firm has a 50-day simple moving average of $0.24 and a 200-day simple moving average of $0.50.
Viracta Therapeutics (NASDAQ:VIRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.10. Sell-side analysts expect that Viracta Therapeutics will post -0.69 earnings per share for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on VIRX
About Viracta Therapeutics
Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
Recommended Stories
- Five stocks we like better than Viracta Therapeutics
- How to Invest in Small Cap Stocks
- Inflation Risk Rising, Key Trades Investors Are Making Now
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Oil Stocks to Watch Before Earnings Come Out
- What is a Death Cross in Stocks?
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.